Tumor suppressor activity of the TGF-β pathway in human cancers

Cytokine and Growth Factor Reviews

Volumn 7, Issue 1, 1996, Pages 93-102

  Markowitz, Sanford D ^a   Roberts, Anita B ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Growth regulation; Growth suppression; Receptors; TGF

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

CELL DIVISION; COLON CANCER; COLON TUMOR; FRAMESHIFT MUTATION; GENE MUTATION; GENETICS; GROWTH REGULATION; HUMAN; MUTATION; NEOPLASM; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; TUMOR SUPPRESSOR GENE;

EID: 0030183051     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/1359-6101(96)00001-9     Document Type: Short Survey

References (123)

1. 1. Markowitz S. Wang J. Myeroff L. et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995, 268, 1336-1338.
2. 2. Myeroff L, Parsons R, Kim S-J, et al. A TGF-beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995, 55, 5545-5547.
3. 3. Parsons R, Myeroff L, Liu B. et al. Microsatellite instability and mutations of the TGF-β type II receptor gene in colorectal cancer. Cancer Res 1995, 55, 5548-5550.
4. 4. Garrigue-Antar L, Muǹoz-Antonia T, Antonia S. Gesmonde J. Vellucci V, Reiss M. Mis-sense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells. Cancer Res 1995, 55, 3982-3987.
5. 5. Park J, Kim S-J, Bang Y-J. et al. Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc Natl Acad Sci USA 1994, 91, 8772-8776.
6. 6. Wang J, Sun L, Myeroff L, et al. Demonstration that mutation of the type II TGF-β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 1995, 270, 22044-22049.
7. 7. Sun L, Wu G, Willson J K V, et al. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 1994, 269, 26449-26455.
8. 8. Roberts A, Sporn M. Peptide growth factors and their receptors. In Sporn M, Roberts A. eds. Handbook of Experimental Pharmacology. Heidelberg, Springer, 1990, 419-472.
9. 9. Massagué J. The transforming growth factor-beta family. Ann Rev Cell Biol 1990, 6, 597-641.
10. 10. Massagué J, Attisano L, Wrana J. The TGF-β family and its composite receptors. Trends Cell Biol 1994, 4, 172-178.
11. 11. Sporn M B, Roberts A B. Autocrine growth factors and cancer. Nature 1985, 313, 747-751.
12. 12. Shull M, Ormsby I, Kier A, et al. Targeted disruption of the mouse transforming growth factor-β gene results in multifocal inflammatory disease. Nature 1992, 359, 693-699.
13. 13. Kulkarni A B, Huh C G, Becker D, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993, 90, 770-774.
14. 14. Filmus J, Kerbel R. Development of resistance mechanisms lo the growth-inhibitory effects of transforming growth factor-β during tumor progression. Curr Opin Oncol 1993, 5, 123-129.
15. 15. Alexandrow M, Moses H. Transforming growth factor β and cell cycle regulation. Cancer Res 1995, 55, 1452-1457.
16. 16. Oberhammer F, Pavelka M, Sharma S, et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc Natl Acad Sci USA 1992, 89, 5408-5412.
17. 17. Rorke E, Jacobberger J. Transforming growth factor-β1 (TGFβ1) enhances apoptosis in human papillomavirus type 16-immortalized human ectocervical epithelial cells. Exp Cell Res 1995, 216, 65-72.
18. 18. Wang C Y. Eshleman J R, Willson J K V, Markowitz S. TGF-β and substrate release are both inducers of apoptosis in a human colon adenoma cell line. Cancer Res 1995, 55, 5101-5105.
19. 19. Huang S, Chakrabarty S. Regulation of fibronectin and laminin receptor expression, fibronectin and laminin secretion in human colon cancer cells by transforming growth factor-β1. Int J Cancer 1994, 57, 742-746.
20. 20. Chakrabarty S. Role of protein kinase C in transforming growth factor β1 induction of carcinoembryonic antigen in human colon carcinoma cells. J Cell Physiol 1992, 152, 494-499.
21. 21. Alexandrow M, Moses H. Transforming growth factor β1 inhibits mouse keratinocytes late in G1 independent of effects of gene transcription. Cancer Res 1995, 55, 3928-3932.
22. 22. Boyd F, Massagué J. Transforming growth factor-β inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor. J Biol Chem 1989, 264, 2272-2278.
23. 23. Markowitz S, Myeroff L, Cooper M, et al. A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene. J Clin Invest 1994, 93, 1005-1013.
24. 24. Martikainen P, Kyprianou N, Issacs J. Effect of transforming growth factor-β on proliferation and death of rat prostatic cells. Endocrinoloav 1990, 127, 2963-2968.
25. 25. Avery A, Paraskeva C, Hall P, Flanders K C, Sporn M, Moorghen M. TGF-β expression in the human colon: differential immunostaining along crypt epithelium. Br J Cancer 1993, 68, 137-139.
26. 26. Lipkin M. Intermediate biomarkers of increased susceptibility to cancers of the large intestine. In Augenlicht L. ed. Cell and Molecular Biology of Colon Cancer. Boca Raton, CRC Press, 1989, 97-109.
27. 27. Gavrieli Y, Sherman Y, Ben-Sasson S. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992, 119, 493-501.
28. 28. Potten C S, Allen T D. Ultrastructure of cell loss in intestinal mucosa. J Ultrastruct Res 1977, 60, 272-277.
29. 29. Pierce D, Gorska A, Chtil A, et al. Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc Natl Acad Sci USA 1995, 92, 4254-4258.
30. 30. Jhappan C, Geiser A G, Kordon E C, et al. Targeting expression of a transforming growth factor β1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J 1993, 12, 1835-1845.
31. 31. Sellheyer K, Bickenbach J R, Rothnagel J A, et al. Inhibition of skin development by overexpression of transforming growth factor β1 in the epidermis of transgenic mice. Proc Natl Acad Sci USA 1993, 90, 5237-5241.
32. 32. Geng Y, Weinberg R. Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc Natl Acad Sci USA 1993, 90, 10315-10319.
33. cdc2 phosphorylation and histone H1 kinase activity is associated with G S-phase growth arrest. Mol Cell Biol 1991, 11, 1185-1194.
34. 34. Ewen M, Sluss H, Whitehouse L, Livingston D. TGFβ inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell 1993, 74, 1009-1020.
35. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994, 371, 257-261.
36. 36. Elbendary A, Berchuck A, Davis P, et al. Transforming growth factor β1 can induce CIP1 WAF1 expression independent of the p53 pathway in ovarian cells. Cell Growth Diff 1994, 5, 1301-1307.
37. 37. Datto M, Li Y, Panus J, Howe D, Xiong Y, Wang X-F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995, 92, 5545-5549.
38. 38. Li C-Y, Suardet L, Little J. Potential role of WAF1 Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. J Biol Chem 1994, 270, 4971-4974.
39. 39. Polyak K, Lee M-H, Erdjument-Bromage H, et al. Cloning of p27Kip1. a cyclin-dependent kinase inhibitor and a potential mediator of extracellular anti-mitogenic signals. Cell 1994, 78, 59-66.
40. 40. Moses H, Yang E, Pietenpol J. TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990, 63, 245-247.
41. 41. Kimchi A, Wang X-F, Weinberg R, Cheifetz S, Massagué J. Absence of TGF-β receptors and growth inhibitory responses in retinoblastoma cells. Science 1988, 240, 196-199.
42. 42. Reiss M, Sartorelli A. Regulation of growth and differentiation of human keratinocytes by type β transforming growth factor and epidermal growth factor. Cancer Res 1987, 47, 6705-6709.
43. 43. Boyd J, Kaufman D, Expression of transforming growth factor β1 by human endometrial carcinoma cell lines: inverse correlation with effects on growth rate and morphology. Cancer Res 1990, 50, 3394-3399.
44. 44. Geiser A, Burmester J, Webbink R, Roberts A, Sporn M. Inhibition of growth by transforming growth factor-β following fusion of two non-responsive human carcinoma cell lines. J Biol Chem 1992, 267, 2588-2593.
45. 45. Damstrup L, Rygaard K, Spang-Thomsen M, Poulson H S. Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2, TGF beta 3 in human small cell lung cancer cell lines. Br J Cancer 1993, 67, 1015-1021.
46. 46. Norgaard P, Damstrup L, Rygaard K, Spang-Thomsen M, Skovgaard H P. Growth suppression by transforming growth factor beta 1 of human small-cell lung cancer cell lines is associated with expression of the type II receptor. Br J Cancer 1994, 69, 802-808.
47. 47. Hoosein N, McKnight M, Levine A, et al. Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-β1. Exp Cell Res 1989, 181, 442-453.
48. 48. Sing G, Ruscetti F, Beckwith M, et al. Growth inhibition of a human Iymphoma cell line: induction of a transforming growth factor-β-mediated autocrine negative loop by phorbol myristate acetate. Cell Growth Diff 1990, 1, 549-557.
49. 49. Kadin M, Cavaille-Coll M, Gertz R, Massagué J, Cheifetz S, George D. Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc Natl Acad Sci USA 1994, 91, 6002-6006.
50. 50. Capocasale R, Lamb R, Vonderheid E, et al. Reduced surface expression of transforming growth factor β receptor type II in mitogen-activated T cells from Sézary patients. Proc Natl Acad Sci USA 1995, 92, 5501-5505.
51. 51. Manning A, Williams A, Game S, Paraskeva C. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor β (TGF β): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-β. Oncogene 1991, 6, 1471-1476.
52. 52. Lin H, Wang X-F, Ng-Eaton E, Weinberg R, Lodish H. Expression cloning of the TGF-β type II receptor a functional transmembrane serine/threonine kinase. Cell 1992, 68, 775-785.
53. 53. Wrana J, Attisano L, Cárcamo J, et al. TGFβ signals through a heteromeric protein kinase receptor complex. Cell 1992, 71, 1003-1014.
54. 54. Moustakas A, Lin H, Henist Y, Plamondon J, O'Connor-McCourt M, Lodish H. The transforming growth factor β receptors types I, II and III form hetero-oligomeric complexes in the presence of ligand. J Biol Chem 1993, 268, 22215-22218.
55. 55. Laiho M, Weis F, Boyd F, Ignotz R, Massagué J. Responsiveness to transforming growth factor-β restored by genetic complementation between cells defective in TGF-β receptors I and II. J Biol Chem 1991, 266, 9108-9112.
56. 56. Laiho M, Weis F, Massagué J. Concomitant loss of transforming growth factor (TGF)-β receptor types I and Il in TGF-β-resistant cell mutants implicates both receptor types in signal transduction. J Biol Chem 1990, 265, 18518-18524.
57. 57. Wrana J, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-β receptor. Nature 1994, 370, 341-347.
58. 58. López-Casillas F, Wrana J, Massagué J. Betaglycan presents ligand to the TGFβ signaling receptor. Cell 1993, 73, 1435-1444.
59. 59. Bassing C, Yingling J, Howe D, et al. A transforming growth factor type I receptor that signals to activate gene expression. Science 1994, 263, 87-89.
60. 60. Franzén P, ten Dijke P, Ichijo H, et al. Cloning of a TGFβ type I receptor that forms a heteromeric complex with the TGFβ type II receptor. Cell 1993, 75, 681-692.
61. 61. Wieser R, Wrana J, Massagué J. GS domain mutations that constitutively activate TβR-1, the downstream signaling component in the TGF-β receptor complex. EMBO J 1995, 14, 2199-2208.
62. 62. Wieser R, Attisano L, Wrana J, Massagué J. Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region. Mol Cell Biol 1993, 13, 7239-7247.
63. 63. Cárcamo J, Zentella A, Massagué J. Disruption of transforming growth factor β signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol Cell Biol 1995, 15, 1573-1581.
64. 64. Brand T, Schneider M. Inactive type II and type I receptors for TGFβ are dominant inhibitors of TGFβ-dependent transcription. J Biol Chem 1995, 270, 8274-8284.
65. 65. Hagan K, Ruiz-Echevarria M, Yong Q, Peltz S. Characterization of cis-acting sequences and decay intermediates involved in nonsense-mediated mRNA turnover. Mol Cell Biol 1995, 15, 809-823.
66. 66. Eshelman J, Markowitz S. Microsatellite instability in inherited and sporadic neoplasms. Curr Opin Oncol 1995. 7, 83-89.
67. 67. Aaltonen L, Peltomäki P, Leach F, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260, 812-816.
68. 68. Ionov Y, Peinado M, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonie carcinogenesis. Nature 1993, 363, 558-561.
69. 69. Thibodeau S, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993. 260, 816-819.
70. 70. Kim H, Jen J, Vogelstein B, Hamilton S, Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994, 145, 148-156.
71. 71. Lynch H. Hereditary colorectal cancer syndromes. In Willson J K V, ed. Colorectal Cancer, Fairlawn, Medical Publishing Enterprises, 1992. 11-17.
72. 72. Liu B, Nicolaides N, Markowitz S. et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nature Genet 1995, 9, 48-53.
73. 73. Risinger J I. Berchuck A, Kohler M F, Watson P, Lynch H T, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993, 53, 5100-5103.
74. 74. Han H-J. Yanagisawa A. Kato Y. Park J-G, Nakamura Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res 1993. 53, 5087-5089.
75. 75. Fishel R, Lescoe M, Rao M, et al. The human mutator gene homolog MSH2 and its association with hereditary non-polyposis colon cancer. Cell 1993, 75, 1027-1038.
76. 76. Leach F, Nicolaides N, Papadopoulos N, et al. Mutations of a MutS homolog in hereditary non-polyposis colorectal cancer. Cell 1993, 75, 1215-1225.
77. 77. Bronner C, Baker S, Morrison P, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994, 368, 258-261.
78. 78. Papadopoulos N, Nicolaides N, Wei Y F, et al. Mutations of a mutL homolog in hereditary colon cancer. Science 1994, 263, 1625-1629.
79. 79. Liu B, Parsons R, Hamilton S, et al. hMSH2 mutations in hereditary non-polyposis colorectal cancer kindreds. Cancer Res 1994, 54, 4590-4594.
80. 80. Nicolaides N, Papadopoulos N, Liu B, et al. Mutations in two PMS homologues in hereditary non-polyposis colon cancer. Nature 1994, 371, 75-80.
81. 81. Papadopoulos N, Nicolaides N, Liu B, et al. Mutations of GTBP in genetically unstable tumors. Science 1995. 268, 1915-1917.
82. 82. Watson P, Lynch H T, Extracolonic cancer in hereditary non-polyposis colorectal cancer. Cancer 1993, 71, 677-685.
83. 83. Mathew S, Murty V S, Cheifetz S, Giorge D, Massagué J, Chaganti R S K. Transforming growth factor receptor gene TGFBR2 maps to human chromosome 3p22. Genomics 1993, 20, 114-115.
84. 84. Whang-Peng J. Kao-Shan C S, Lee E C, et al. Specific chromosome defect associated with human small cell lung cancer: Deletion 3p(14-23). Science 1982, 215, 181-182.
85. 85. Falk L A, De Benedetti F, Lohrey N, et al. Induction of transforming growth factor-beta 1 (TGF-beta 1), receptor expression and TGF-beta 1 protein production in retinoic acid-treated HL-60 cells: possible TGF-beta 1-mediated autocrine inhibition. Blood 1991, 77, 1248-1255. Blood 1991, 77, 1248-1255.
86. 86. Letterio J J, Anzano M A, Roberts A B, Spron M B. Novel vitamin D analog enhances differentiating effects of transforming growth factor beta-1 (TGF-β) in myeloid leukemic cell lines. Proc Am Ass Cancer Res 1993, 34, 46.
87. 3 in NRP-152 rat prostatic epithelial cells. J Cell Physiol 1996, 166, 231-239.
88. 88. Roberts A B, Sporn M B. Mechanistic interrelationships between two superfamilies: the steroid/retinoid receptors and transforming growth factor-β Cancer Surveys 1992, 14, 205-220.
89. 89. Kim I Y, Ahn H-J, Zelner D, et al. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res 1996, 56, 44-48.
90. 90. Wang J, Han W X W, et al. Reduced expression of transforming growth factor-β type 1 receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem (submitted).
91. 91. Ciernik I F, Ciernik B, Cockerell C. Minna J, Gazdar A, Carbone D. Expression of transforming growth factor β and transforming growth factor β receptors on AIDS-associated Kaposi's sarcoma. Clin Cancer Res 1995, 1, 1119-1124.
92. 92. Matztik M M, Finegold M J, Su J-G J, Hsueh A J W, Bradley A. x-Inhibin is a tumor-suppressor gene with gonadal specificity in mice. Nature 1992, 360, 313-319.
93. 93. Wu S, Theodorescu D, Kerbel R, et al. TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an anti-sense expression vector. J Cell Biol 1992, 116, 187-196.
94. 94. Geiser A G, Kim S J, Roberts A B, Sporn M B. Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-ras oncogene. Mol Cell Biol 1991, 11, 84-92.
95. 95. Kim S J, Angel P, Lafyatis R, et al. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 1990, 10, 1492-1497.
96. 96. Birchenall-Roberts M C, Ruscetti F W, Kasper J, et al. Transcriptional regulation of the transforming growth factor beta 1 promoter by v-src gene products is mediated through the AP-1 complex. Mol Cell Biol 1990, 10, 4978-4983.
97. 97. Wakefield L M, Colletta A A, McCune B K, Sporn M B. Roles for transforming growth factors-β in the genesis, prevention, and treatment of breast cancer. In Dickson R B, Lippman M E, eds. Genes, Oncogenes, and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer. Boston, Kluwer Academic Publishers, 1991, 97-136.
98. 98. Suardet L, Gaide A C, Calmes J M, et al. Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors beta 1 and beta 2. Cancer Res 1992, 52, 3705-3712.
99. 99. Glick A B, Kulkarni A B, Tennenbaum T, et al. Loss of expression of transforming growth factor β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Acad Sci USA 1993, 90, 6076-6080.
100. 100. Glick A B, Lee M M, Darwiche N, Kulkarni A B, Karlsson S. Yuspa S H. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Devel 1994, 8, 2429-2440.
101. 101. Cheng K C, Loeb L A. Genomic instability and tumor progression: mechanistic considerations. Adr Cancer Res 1993, 60, 121-156.
102. 102. Glick A B, Lee M M, Wu I H, Weinberg W, Yuspa S H. Genomic instability in cell lines derived from TGF-β1 null keratinocytes. Proc. AACR 1996, 36, A3239.
103. 103. Kornfield S. Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. Ann Rev Biochem 1992, 61, 307-330.
104. 104. Dennis P A. Rifkin D B. Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose 6-phosphate insulin-like growth factor II receptor. Proc Natl Acad Sci USA 1991. 88, 580-584.
105. 105. Jirtle R L, Haag J D, Ariazi E A, Gould M N. Increased mannose 6-phosphate insulin-like growth factor II receptor and transforming growth factor 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 1993, 53, 3849-3852.
106. 106. De Souza A T, Hankins G R. Washington M K. Orton T C. Jirtle R L. M6P IGF24 gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nature Genet 1995, 11, 447-449.
107. 107. De Souza A T, Hankins G R, Washington M K, Fine R L, Orton T C, Jirtle R L. Frequent loss of hererozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995, 10, 1725-1729.
108. 108. Chen R-H, Miettinen P, Maruoka E M, Choy L, Derynck R. A WD-domain protein that is associated with, and phosphorylated by, the type II TGF-β receptor. Nature 1995, 377, 548-552.
109. 109. Wang T, Donahoe P. Zervos A. Specihc interaction of type I receptors of the TGF-β family with the immunophilin FKBP-12. Science 1994, 265, 674-676.
110. 110. Kawabata M, Inamura T. Miyazono K. et al. Interaction of the transforming growth factor-β type I receptor with farnesyltransferase-x. J Biol Chem 1995. 270, 29628-29631.
111. 111. Wang T, Donahoe P. p21ras farnesyltransferase alpha subunit in TGF-β and activin signaling. Science (in press).
112. 112. Yamaguchi K, Shirakabe K. Shibuya H, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 1995, 270, 2008-2011.
113. 113. Sekelsky J J, Newfeld S J, Raftery L A, et al. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 1995, 139, 1347-1358.
114. 114. Hahn S A, Schutte M, Hoque A T M S, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 350-353.
115. 115. Nobori T, Miura K, Wu D J. et al. Deletions of the cyclindependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368, 753-756.
116. 116. Jen J, Harper J, Bigner S, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994, 54, 6353-6358.
117. 117. Cross M, Dexter T M. Growth factors in development, transformation, and tumorigenesis. Cell 1991, 64, 271-280.
118. 118. Cantley L C, Auger K R, Carpenter C, et al. Oncogenes and signal transduction. Cell 1991, 64, 281-302.
119. 119. Yanagihara K, Tsumuraya M. Transforming growth factor β1 induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res 1992, 52, 4042-4045.
120. 120. Lin J-K, Chou C-K. In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor β1. Cancer Res 1992, 52, 385-388.
121. 121. Filmus J, Zhao J, Buick R. Over-expression of H-ras oncogene induces resistance to the growth-inhibitory action of transforming growth factor beta-1 (TGF-β1) and alters the number and type of TGF-β1 receptors in rat intestinal epithelial cell clones. Oncogene 1992, 7, 521-526.
122. 122. Gerwin B, Spillare E, Forrester K, et al. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta. Proc Natl Acad Sci USA 1992, 89, 2759-2763.
123. 123. Okamoto A, Jiang W. Kim S-J, et al. Overexpression of human cyclin D1 reduces transforming growth factor β (TGF-β) type II receptor and growth inhibition by TGF-β1 in an immortalized human esophageal epithelial cell line. Proc Natl Acad Sci USA 1994, 91, 11576-11580.